Profile cover photo
Profile photo
DelMar Pharmaceuticals, Inc.
19 followers -
DelMar (NASDAQ:DMPI) develops cancer therapies in new indications where patients have failed/unlikely to respond to modern therapy. Clinical trial in GBM
DelMar (NASDAQ:DMPI) develops cancer therapies in new indications where patients have failed/unlikely to respond to modern therapy. Clinical trial in GBM

19 followers
About
Posts

Post has attachment
If you or a loved one has recently been diagnosed with a brain tumor, the American Brain Tumor Association outlines the first steps you should take in understanding your diagnosis.
Add a comment...

Every 23 minutes another woman is diagnosed with ovarian cancer. Learn how you can raise awareness from the Ovarian Cancer Research Fund Alliance:
Add a comment...

Post has attachment
More than 28,000 children are estimated to be living with a brain tumor in the US. Learn more brain tumor facts from the National Brain Tumor Society:
Add a comment...

Post has attachment
Brain tumors are the leading cancer-related cause of death in kids 19 years of age and younger, surpassing leukemia. Support the National Brain Tumor Society's Defeat Pediatric Brain Tumor initiative a powerful, unique global research and drug discovery program which aims to improve clinical outcomes for pediatric brain tumor patients.
Defeat Pediatric Brain Tumors
Defeat Pediatric Brain Tumors
defeatpediatricbraintumors.org
Add a comment...

Post has attachment
Dr. Roisin O'Cearbhaill, a medical oncologist who specializes in gynecological cancers at Memorial Sloan Kettering Cancer Center, explains what young people should know about ovarian cancer and the symptoms to be aware of.
Refinery29
Refinery29
refinery29.com
Add a comment...

Post has attachment
Are you at risk for ovarian cancer? Find out from the National Ovarian Cancer Coalition:
Add a comment...

Post has attachment
Mothers of childhood brain tumor patients share the impact the diagnosis had on their lives and the need for more research into better treatments.
Add a comment...

Post has attachment
In an op-ed piece for The Hill, DelMar President & COO Jeffrey Bacha writes about the Senate's hearings on drug pricing and how the government regulations impact development-stage pharmaceutical and biotech companies. Mr. Bacha highlights three key ways the government can help to lower costs and assist biotech innovators developing lifesaving therapies.
Add a comment...

Post has attachment
DelMar today provided an overview of three scientific posters presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) held on November 16-19, 2017 in San Francisco, CA. DelMar reported that 96% of patients enrolled were alive at the time of the analysis and 40% of patients enrolled were reported to have achieved stable disease as assessed by MRI following treatment with VAL-083 as a single agent. "While it is too early to interpret overall survival results from this study, the substantial disease control observed to date in the treatment recurrent GBM, ‎an aggressive tumor that can double in size within 6-8 weeks, is an important and positive observation at this stage," said Mr. Saiid Zarrabian, DelMar's Interim Chief Executive Officer. For full details, read today's press release:
Add a comment...

Post has attachment
Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. For more information, visit the Mayo Clinic:
Add a comment...
Wait while more posts are being loaded